inspection – Page 76

Validation gaps identified during change control – risk-based validation alignment

Mitigating Validation Gaps Found During Change Control: A Comprehensive Playbook Validation gaps identified during change control can lead to significant compliance and quality issues in pharmaceutical manufacturing. They often result…

System access controls weak during validation lifecycle – preventing repeat Part 11 findings

Strengthening System Access Controls Throughout the Validation Lifecycle Pharmaceutical companies often face challenges related to system access controls, particularly during the validation lifecycle. Weak access controls can lead to significant…

CSV compliance weak during lifecycle management – risk-based validation alignment

Enhancing CSV Compliance Throughout Lifecycle Management for Regulatory Readiness Pharmaceutical manufacturing often grapples with the challenge of maintaining compliance in computer system validation (CSV) during the lifecycle of software and…

ERES controls not implemented during inspection walkthrough – CAPA and revalidation strategy

Strategies for Addressing ERES Control Failures During Inspection Walkthroughs When regulatory inspectors notice lapses in electronic records and electronic signatures (ERES) controls during walkthroughs, it poses a significant risk for…

Incomplete validation lifecycle during inspection readiness – risk-based validation alignment

Mitigating Risks of Incomplete Validation Lifecycles for Inspection Readiness In the pharmaceutical manufacturing landscape, maintaining compliant operational standards is critical. One pressing issue is managing the risks associated with an…

Record retention failures during inspection walkthrough – preventing repeat Part 11 findings

Preventing Record Retention Failures During Inspection Walkthroughs In the highly regulated pharmaceutical industry, maintaining adequate record retention practices is crucial for compliance during inspections. Given the heightened scrutiny from regulatory…

Requalification overdue during inspection readiness – risk-based validation alignment

Strategic Playbook for Managing Requalification Overdue During Inspection Readiness In the dynamic environment of pharmaceutical manufacturing, inspection readiness is paramount. A critical issue many companies face is having overdue requalifications…

Electronic signatures misused during system operation – 21 CFR Part 11 compliance gaps

Addressing Compliance Gaps in Electronic Signature Use During System Operation The use of electronic signatures in pharmaceutical manufacturing and quality control envelops critical regulatory compliance under 21 CFR Part 11.…

Incomplete validation lifecycle during system upgrades – preventing repeat validation findings

Preventing Repeat Findings from Incomplete Validation during System Upgrades Incomplete validation of systems during upgrades is a chronic issue faced by many pharmaceutical manufacturers. Such lapses can lead to regulatory…

Electronic signatures misused during system operation – inspection evidence requirements

“`html Addressing Misuses of Electronic Signatures During System Operation: A Practical Guide In today’s digital age, the misuse of electronic signatures during system operation is an increasingly pressing issue for…

Incomplete validation lifecycle during inspection readiness – inspection evidence expectations

Understanding and Addressing Incomplete Validation Lifecycle in Inspection Readiness Incomplete validation during the manufacturing lifecycle poses significant risks during inspections, potentially leading to regulatory non-compliance. Pharmaceutical manufacturing professionals—encompassing roles in…

Electronic signatures misused during system upgrade – preventing repeat Part 11 findings

Mitigating Risks of Misuse of Electronic Signatures During System Upgrades In the landscape of pharmaceutical manufacturing, the rise of electronic records and signatures is accompanied by significant compliance challenges. Misuse…